[New therapeutic agents in the management of multiple sclerosis].
THERAPEUTIC ADVANCES: Several effective therapies for multiple sclerosis capable of modifying the disease course in certain patients are now available in France.
Interferon beta-1b and interferon beta-1a have been given specific marketing approval in France for ambulatory patients with active relapsing-remitting multiple sclerosis. Interferon beta-1b has been shown to have a beneficial effect in progressive multiple sclerosis.
This drug has a temporary authorization in France for ambulatory patients with relapsing-remitting multiple sclerosis who cannot tolerate interferon.


CONCLUSIONS
Other promising therapeutic options (mitoxantrone, intravenous immunoglobulins, drug associations) are under evaluation.
Besson
G
G
Gerard.besson@ujf-grenoble.fr
Carpentier
F
F
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D000068717:Glatiramer Acetate; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage; D007275:Injections, Intravenous; D016899:Interferon-beta / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use*; D011446:Prospective Studies
D000276:Adjuvants, Immunologic; D007136:Immunoglobulins; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta